

**Contact:**

Douglas Doerfler  
Chief Executive Officer  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

## **MaxCyte Strengthens Leadership Team**

*Arthur Mandell elected to Board of Directors*

*Judith Hedstrom joins as SVP, Corporate and Business Development*

*Carl June, M.D. added to Scientific and Medical Advisors*

**Gaithersburg, MD, September 13, 2006** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale cell loading systems for cellular therapy, including personalized cellular approaches, announces the addition of three seasoned individuals to its leadership team. Arthur Mandell, was elected to MaxCyte’s Board of Directors, Judith Hedstrom joined the Executive Team in the new role of Senior Vice President, Corporate and Business Development and Carl June, MD became a member of MaxCyte’s distinguished roster of Scientific and Medical Advisors.

“We are delighted that these experienced and accomplished individuals have joined the MaxCyte leadership team. As we go forward, their contributions will help build on the successes we have enjoyed this year and position us well to expand our role in the therapeutic development arena”, said Doug Doerfler, President and CEO of MaxCyte Inc. “Art Mandell has a strong track record as a seasoned biopharma industry executive and adds additional strategic perspective at all stages of corporate development. Judy Hedstrom brings substantial experience in clinical product development, commercialization and licensing to our team. Carl June is a world-class leader in the area of immunotherapy who has been working with MaxCyte and will continue to lend important expertise in our pursuit of new applications for cell-based therapeutics,” he added.

### **About Art Mandell**

Mr. Mandell joined Prestwick Pharmaceuticals in November 2005 as President and COO and currently serves as Executive Strategic Advisor. Mr. Mandell has also served as a Director of the Company since October 2005. Mr. Mandell has over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a Director of Collective Therapeutics, Inc., a Maryland-based monoclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Collective, Mr. Mandell was President, Chief Executive Officer, and still serves as a Director of Stemron Corporation, a therapeutic stem cell company in Gaithersburg, Maryland. In addition, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (NASDAQ: HGSI), in Gaithersburg, Maryland. Mr. Mandell serves as a Director for the Maryland High Technology Council and as a Director for the MdBio organization. Mr. Mandell was elected to the Board of Directors of MaxCyte in May, 2006.

### **About Judith Hedstrom**

Ms. Hedstrom joined MaxCyte in August, 2006 after four years at Alteon Inc. where she was Chief Operating Officer and responsible for all commercial and clinical operations. She spent six years at McKinsey & Company as member of the Pharmaceutical and Medical Products leadership team serving both large and emerging biopharmaceutical clients. With over 25 years of diverse experiences in the health care industry, Ms. Hedstrom has acquired substantial expertise in development and commercialization of new technologies in the life sciences. She previously served as Vice President, Business Development at APACHE Medical Systems and as Senior Consultant at The Wilkerson Group, Inc. She began her career in product development at Baxter International. Ms. Hedstrom holds an M.B.A in Finance and Marketing and a B.A. in Chemistry from the University of Chicago.

### **About Carl June, M.D.**

Dr. Carl June, M.D. is Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania and is an Investigator of the Abramson Family Cancer Research Institute. He is board certified in Internal Medicine and Medical Oncology. He is a graduate of the United States Naval Academy in Annapolis, and Baylor College of Medicine in Houston. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas at the Fred Hutchinson Cancer Research Center in Seattle from 1983 - 1986. Dr. June founded the Immune Cell Biology Program and was head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995. He rose to Professor in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda, Maryland before assuming his current position as of February 1, 1999. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy. He was a scientific founder of Xcyte, a Seattle-based company involved with cell-based therapeutics. Dr. June became a member of MaxCyte's Scientific and Medical Advisors in September, 2006.

### **About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and several preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

**For more information, visit <http://www.maxcyte.com>.**

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###